Neuro Lab · DeCure for X
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for hereditary sensory and autonomic neuropathy type 4 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for hereditary sensory and autonomic neuropathy type 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
neurotrophic receptor tyrosine kinase 1 (NTRK1) — NTRK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 2IFG · 3.4 Å · ligand 2-acetamido-2-deoxy-alpha-D-glucopyranose (NDG). Experimental structure, not a prediction.
Hereditary sensory and autonomic neuropathy type 4 is a rare condition. A 2019 case report of a three-year-old boy with the disease describes it as associated with insensitivity to pain and temperature and anhidrosis. That report states there is no definitive treatment available presently for this condition. A 2023 case report of a 29-year-old man with hereditary sensory and autonomic neuropathy type II notes that despite efforts to maintain an optimal quality of life, the lack of an early diagnosis led to an unfavourable prognosis and life condition.
A 1995 report describes a kindred with an autosomal dominantly inherited sensory neuropathy associated with sensorineural hearing loss and early-onset dementia, noting clinical variability among kindreds and suggesting genetic heterogeneity. A 2010 review of sensory neuropathies states that diagnostic methods for both acquired and hereditary sensory neuropathies have progressed, leading to earlier and more specific diagnoses. That review also says much progress remains to be made regarding symptomatic and disease-modifying therapy for a range of sensory neuropathies, including those from hereditary causes.
The 2010 review mentions that intravenous immunoglobulin and tumour necrosis factor-alpha inhibitors show promise for some dysimmune sensory neuropathies or neuronopathies, but these are not hereditary sensory and autonomic neuropathy type 4. No drug is tested or reported for HSAN type 4 in any of these abstracts. No survival or response rates are given for any treatment in this disease.
What is still missing is any disease-modifying therapy for HSAN type 4, any clinical trial testing a drug for this specific subtype, and any patient stratification or biomarker that could guide a future trial. The condition remains without a definitive treatment.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractWe report a kindred with autosomal dominantly inherited sensory neuropathy associated with sensorineural hearing loss and early-onset dementia. This kindred provides further evidence of the clinical variability among kindreds with hereditary sensory neuropathy, suggesting genetic heterogeneity.
https://doi.org/10.1212/wnl.45.3.560AbstractPURPOSE OF REVIEW: The present review focuses on recent developments in diagnosis and treatment of sensory neuropathies. It does not seek to establish a comprehensive classification of sensory neuropathies, nor treatment guidelines per se. RECENT FINDINGS: Diagnostic criteria and guidelines have been developed for distal symmetric polyneuropathies, small fiber sensory neuropathies and sensory neuronopathies. Novel diagnostic tools such as skin biopsies now allow diagnosis of small fiber sensory neuropathies. Genetic testing has defined new subtypes of mitochondrial neuropathies and inherited neuropathies with sensory involvement. Intravenous immunoglobulin and tumor necrosis factor-alpha inhibitors show promise for some dysimmune sensory neuropathies or neuronopathies. Additional options for management of neuropathic pain are emerging. SUMMARY: Diagnostic methods for both acquired and hereditary sensory neuropathies have progressed in recent years, leading to earlier and more specific diagnoses and a better understanding of disease mechanisms. Much progress remains to be made regarding symptomatic and disease-modifying therapy for a range of sensory neuropathies, including those due to diabetes, HIV infection and from dysimmune or hereditary causes.
https://doi.org/10.1097/wco.0b013e32833c7a19AbstractWe describe the follow-up of a 29-year-old man diagnosed with hereditary sensory and autonomic neuropathy type II, including the different complications that presented since his childhood. Despite efforts to maintain an optimal quality of life, the lack of an early diagnosis led to an unfavorable prognosis and life condition.
https://doi.org/10.1002/ccr3.7015AbstractHereditary Sensory and Autonomic Neuropathy (HSAN) is a rare group of diseases involving varying degrees of peripheral nervous system. It is classified into five main types. HSAN type 4 is associated with insensitivity to pain and temperature and anihidrosis. The method of this study was to authors present a case report of a 3 year-old boy with Hereditary Sensory and Autonomic Neuropathy Type 4 presenting with chronic ulcers. Conclusions of this study was to HSAN type IV is a rare condition. There is no definitive treatment available presently for this condition.
https://doi.org/10.18203/2320-6012.ijrms20195025Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
